Professor Chan has conducted more than 80 clinical trials (including early phase oncology studies) since 2000. He led pivotal studies in setting new treatment standard in multimodality approaches in nasopharynx cancer and pioneered immunotherapeutic and targeted therapeutics in nasopharynx cancer.
Professor Ma has conducted over 70 Phase I-II-III clinical trials in oncology and served on numerous advisory boards of major pharmaceutical companies. She served as the Vice-President of the Hong Kong Nasopharyngeal Cancer Study Group, President of the Hong Kong Head and Neck Society. Currently, she is the chairman of Phase 1 Clinical Trials Review Panel of Joint CUHK-NTEC Clinical Research Ethics Committee.
Experience of involvement in over 70 Phase I to III clinical trials since 2005 with special clinical interest in internal medicine and endocrinology.
Professor Tomlinson has conducted over 80 bioequivalence and 20 Phase I clinical trials, including first-in-man studies, in the past 30 years, with special interests in pharmacogenomics and ethnic differences in drug responses, lipid disorders, hypertension and diabetes.
Experience as PI/Co-PI in more than 50 local and international oncology Phase I-II-III clinical trials. Dr. Loong’s clinical interest includes sarcoma medical oncology, neuro-oncology, thoracic oncology, experimental therapeutics, and palliative care.
Dr. Ozaki conducted close to 100 pharmaceutical sponsored multicentre international trials in all phases. She has been recognized as the top recruiting investigator in numerous studies and also has extensive experience in internal and external audits, and has been audited by the US FDA.
Dr. Chow is a clinical pharmacologist with a special interest in evaluation of novel glucose lowering drugs or formulations as well as diabetes technology. She has conducted early phase/experimental human research studies in UK and Hong Kong. Her special interests include evaluation continuous glucose monitoring devices involving hypoglycaemic and hyperglycaemic challenges, glucose clamp studies in the evaluation of drug action, beta cell function and counter-regulatory responses to hypoglycaemia.